|Title:||Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection||Authors:||Tsou, Hsiao-Hui
Hsiung, Chao A
|Keywords:||Antiviral therapy; Chemotherapy; Hepatitis B reactivation; Rituximab||Issue Date:||21-Jun-2019||Source:||Journal of the Formosan Medical Association = Taiwan yi zhi||Abstract:||
Hepatitis B virus (HBV) reactivation may occur in >10% of patients with lymphoma and resolved HBV infection who undergo rituximab-containing chemotherapy. Preventive strategies may have marked impact on resource allocation in HBV endemic areas. This study aims to compare the cost-effectiveness between prophylactic antiviral therapy and HBV DNA monitoring for the prevention of HBV-related complications.
|Appears in Collections:||微生物學科所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.